RE: re: conjuchem and ir7Now I'm pissed off.....For you to say that we will win or lose is to say that one therapy will be good for everyone. This just is not the case. There are 3 types of Diabetes and Billions of people......For you to say if TTH "INT" proves successful then CJC will roll over and die is crazy and shows your knowledge of CJC.They have more in the pipelines my friend, but not only that,their proprietary "DAC" which is , at this time, what they are mostly valued on, is highly regarded to not only extend the halflife of GLP-1, but to have an extraordinary ability to work with a multitude of other peptides in combination.....DAC can reduce a drugs toxicity profile because the 'in vivo bioCONJUcation' ( thus CONJUchem ) process bonds the peptide to albumin ( most abundant protein in serum ) and albumin DOES NOT cross the blood-brain barrier and is not metabolized by the kidney or liver. Albumin has a long half life of 14-20 days!!GET IT? CJC is valued not on their diabetes research advances alone...'DAC is Blockbuster'.....Just as TTH is not valued on their diabetes pipeline alone, (although I would say TTH is valued more on it than CJC is at this time) TTh also has other pipelines to advance let alone the technology they have in their back pocket,lets talk Stem Cell Regeneration......Parkinsonism......Alzheimers.....Stroke. TTH has a broad Patent Position for all the above. They are a leader in Regenerative therapy! YES 'INT' could be the medical advance of the century.....and we'll soon see!!!You want to talk value? Think about it......NEURONAL STEM CELL REGENERATION.TTH is positioned to take advantage of these Patents when they so desire.....one step at a time.............................................